MedPath

FDA Issues Complete Response Letter for Xspray Pharma's Dasynoc in CML and ALL

• The FDA issued a Complete Response Letter (CRL) for Dasynoc, Xspray Pharma's treatment for chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL). • The FDA requests additional labeling information and pre-approval inspection details, but does not question stability or clinical data. • Dasynoc leverages Xspray’s HyNap technology, offering potential benefits such as lower dosing and co-administration with acid-reducing agents. • Xspray Pharma is working to address the FDA's requests and anticipates providing an updated timeline for NDA resubmission soon.

Xspray Pharma AB has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Dasynoc, a novel treatment for chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL). The FDA's response, received July 26, 2024, indicates that while no additional clinical studies are required and submitted stability or clinical data are not in question, further information is needed regarding labeling comprehension and the pre-approval inspection conducted at the third-party manufacturing site in June 2024. This development delays the anticipated September launch of Dasynoc.
To address the FDA's concerns, Xspray Pharma plans to collaborate with its third-party manufacturer to fulfill the requests related to the pre-approval inspection. The FDA has also suggested a dialogue with Xspray to refine the labeling strategy. Per Andersson, CEO of Xspray Pharma, expressed confidence in the company's ability to address these requests promptly, emphasizing the importance of Dasynoc as a new treatment option for CML patients, particularly those who require co-medication with acid-reducing agents.

Dasynoc: Addressing Unmet Needs in CML and ALL Treatment

Dasynoc is designed to improve upon existing dasatinib treatments for CML and ALL by utilizing Xspray's patented HyNap Technology. This technology allows for bioequivalence at a 30% lower dose of dasatinib, potentially reducing side effects and improving patient compliance. Furthermore, Dasynoc aims to provide more precise and predictable bioavailability, ensuring patients receive the intended therapeutic benefit. A key advantage of Dasynoc is its compatibility with acid-reducing agents (ARAs), including proton pump inhibitors (PPIs), H2 antagonists, and antacids.
The need for TKI and ARA co-administration is common in CML patients. Data presented at the American Society of Clinical Oncology showed that 54% of CML patients were prescribed a PPI despite existing warnings about potential interactions. A separate study indicated that the 5-year overall survival was reduced by 15% in patients who took both a TKI and a PPI, highlighting the clinical significance of Dasynoc's ARA compatibility.

Implications and Next Steps

While the CRL represents a setback, Xspray Pharma remains committed to bringing Dasynoc to market. The company is working to address the FDA's requests and expects to provide an updated timeline for NDA resubmission in the coming weeks. The potential benefits of Dasynoc, particularly its ability to be co-administered with ARAs without compromising efficacy, could significantly improve the treatment landscape for CML and ALL patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Rejects Lexicon's Zynquista for Type 1 Diabetes and Chronic Kidney Disease

The FDA issued a Complete Response Letter for Lexicon's Zynquista (sotagliflozin) for type 1 diabetes and chronic kidney disease, marking its second rejection.
The decision aligns with a prior advisory committee vote citing concerns that the drug's benefits do not outweigh the risks, particularly diabetic ketoacidosis.

Datopotamab Deruxtecan Granted FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC

The FDA granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for EGFR-mutated non-small cell lung cancer (NSCLC).
The designation is based on Phase 2 TROPION-Lung05 data, indicating a potential benefit in previously treated patients.

Datopotamab Deruxtecan BLA Submitted to FDA for EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo submitted a BLA to the FDA for datopotamab deruxtecan (Dato-DXd) to treat adults with metastatic or locally advanced EGFR-mutated NSCLC who have received prior treatment.
The BLA submission is based on data from the phase 2 TROPION-Lung05 study and pooled analysis from TROPION-Lung01, demonstrating enhanced efficacy in EGFR-mutant NSCLC.

AstraZeneca and Daiichi Sankyo Seek FDA Approval for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd).
The BLA targets the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies.

AstraZeneca and Daiichi Sankyo Seek Accelerated Approval for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo submitted a Biologics License Application to the FDA for datopotamab deruxtecan to treat advanced EGFR-mutated non-small cell lung cancer.
The BLA is based on Phase II TROPION-Lung05 trial results, evaluating the drug's efficacy and safety in patients who progressed after platinum-based chemotherapy and a TKI.

Xspray Pharma Plans Dasynoc NDA Resubmission After Positive FDA Meeting

Xspray Pharma plans to resubmit its New Drug Application (NDA) for Dasynoc in Q4 2024, following constructive feedback from the FDA.
The FDA recommended minor adjustments to Dasynoc's tablet strengths to mitigate medication errors, with new batches already in production.

FDA Rejects Lykos Therapeutics' Midomafetamine for PTSD, Demands Additional Phase 3 Trial

The FDA issued a complete response letter for Lykos Therapeutics' NDA for midomafetamine capsules, intended to treat PTSD in adults, citing insufficient data.
Lykos plans to request a meeting with the FDA to discuss the agency's recommendations and seek reconsideration of the decision regarding midomafetamine.

Orexo Receives Complete Response Letter from FDA for High-Dose Naloxone (OX124) for Opioid Overdose

Orexo received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for OX124, a high-dose naloxone rescue medication.
The FDA's CRL indicates the need for an additional Human Factors (HF) study and further technical data on the final commercial product.

Patritumab Deruxtecan BLA Receives CRL from FDA Due to Manufacturing Inspection

The FDA issued a Complete Response Letter (CRL) for patritumab deruxtecan, intended for EGFR-mutated non-small cell lung cancer, due to findings at a third-party manufacturing facility.
The CRL did not raise concerns regarding the efficacy or safety data submitted in the Biologics License Application (BLA) for the drug.

FDA Rejects Mallinckrodt's Abuse-Deterrent Roxicodone Reformulation

The FDA issued a Complete Response Letter for SpecGx LLC's abuse-deterrent, immediate-release reformulation of Roxicodone (oxycodone hydrochloride) tablets.
The agency provided guidance on areas needing further evaluation before the NDA can be resubmitted for potential approval.

Reference News

[1]
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
drugs.com · Jul 26, 2024

Xspray Pharma received a Complete Response Letter from the FDA for Dasynoc, a CML and ALL treatment, requesting addition...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy